Scarica l'app Stockscreener
21.76
2.90%
-0.65
Pre-mercato:
21.76
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
Tyra Biosciences, Inc. (TYRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bank of America Corp DE Purchases 349,732 Shares of Tyra Biosciences, Inc. $TYRA - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Tyra Biosciences, Inc. (TYRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89 - MarketBeat
ETFs Investing in Tyra Bioscience, Inc Stocks - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tyra Biosciences, Inc. (TYRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Paradigm Biocapital Advisors LP Adds 1,644,846 Shares of Tyra Bi - GuruFocus
Equities Analysts Set Expectations for TYRA FY2026 Earnings - MarketBeat
Tyra Biosciences (TYRA) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
(TYRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Tyra Biosciences, Inc. (TYRA) Investigation: Bronstein, Gewirtz - The National Law Review
Tyra Biosciences (NASDAQ:TYRA) Trading Down 6.7% on Analyst Downgrade - MarketBeat
Bladder Cancer Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight - Barchart.com
Oppenheimer reiterates Outperform rating on Tyra Biosciences, $40 price target - TradingView
Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating - marketscreener.com
H.C. Wainwright cuts Tyra Biosciences price target to $29 on dilution - Investing.com
Tyra Biosciences (NASDAQ:TYRA) Price Target Lowered to $29.00 at HC Wainwright - MarketBeat
HC Wainwright & Co. maintains Buy rating on Tyra Biosciences, $29 price target - TradingView
Biotech fund group reports stake in Tyra Biosciences (NASDAQ: TYRA) — here’s how much of the company it holds - Stock Titan
Press Releases about Tyra Biosciences, Inc.Common Stock (Nasdaq:TYRA) - FinancialContent
Fuhrman Alan Acquires Additional 951 Shares, Holding 37,115 Tyra Biosciences Stocks Post-Award - Kalkine Media
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Unveiling a 97.71% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Tyra Biosciences (NASDAQ: TYRA) CEO lifts stake to 1,438,495 shares - Stock Titan
Stock grant lifts Tyra Biosciences (NASDAQ: TYRA) finance VP stake to 11,258 shares - Stock Titan
CFO adds shares in Tyra Biosciences (TYRA) via plan - Stock Titan
Tyra Biosciences (TYRA) investor uses capped warrants to reach 19.99% stake - Stock Titan
RA Capital buys $0.001-share warrants in Tyra Biosciences (TYRA) - Stock Titan
Investor group reports over 5% stake in Tyra Biosciences (TYRA) - Stock Titan
Tyra Biosciences faces securities fraud probe a... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - PR Newswire
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? - Yahoo Finance
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets - Yahoo Finance
Tyra Biosciences Announces $400 Million Public Offering of Common Stock and Pre-Funded Warrants - Kalkine Media
Squarepoint Ops LLC Purchases 43,311 Shares of Tyra Biosciences, Inc. $TYRA - MarketBeat
Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Tyra Bioscience Shares Rise After Pricing $400 Million Offering - marketscreener.com
Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday - Benzinga
Tyra Biosciences prices $400 million stock offering By Investing.com - Investing.com Nigeria
Tyra Biosciences Insider Verjee Rehan Acquires 972 Shares at $20.58 Each (NASDAQ: TYRA) - Kalkine Media
Tyra Bioscience Prices $400 Million Offering of Shares and Warrants - marketscreener.com
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - TradingView
Why is Tyra Biosciences stock surging today? By Investing.com - Investing.com Canada
Tyra Biosciences (TYRA) director adds shares in open-market buy - Stock Titan
Tyra Biosciences (NASDAQ:TYRA) Director Buys $20,003.76 in Stock - MarketBeat
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $30 to $59 - Moomoo
Dabogratinib Shows Early Activity in FGFR3-Altered Low-Grade NMIBC - CancerNetwork
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data - Investing.com
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data By Investing.com - Investing.com Canada
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBCSlideshow (NASDAQ:TYRA) 2026-09-10 - Seeking Alpha
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $30 - moomoo.com
Dabogratinib Shows Early Efficacy Signal in FGFR3-Altered NMIBC - Targeted Oncology
Tyra Biosciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: oral drug push - Investing.com Canada
Balversa reversa? Tyra’s bladder cancer drug hits in phase II - BioWorld News
Tyra disappoints investors with bladder cancer data - BioPharma Dive
Why This Biotech Stock Just Plummeted To A 10-Month Low - Investor's Business Daily
TYRA: Oral FGFR3 inhibitor shows robust efficacy and safety, advancing to phase III for MIBC - TradingView
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is Tyra Biosciences Stock Sinking Wednesday? - Benzinga
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):